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When Is the Juice
Worth the Squeeze?
Eileen Salinsky, Principal Research Associate
OVERVIEW — This paper provides an overview of clinical preventive services, including a definition of such services and the role of the U.S. Preventive Services Task Force in recommending which services should be routinely
offered to patients. It also describes efforts to analyze the cost effectiveness of
clinical preventive services and reviews the insurance coverage policies of
private and public payers. Barriers to increased uptake of appropriate services are discussed, and policy-relevant issues are summarized.
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The health care system is often derided as a “sick care” system that focuses predominately on treating disease rather than promoting health.
While this characterization may be accurate when viewed in terms of
dollars spent or number of services used, clinical preventive services are,
nevertheless, a pivotal and highly visible aspect of medical care. For many
fortunate Americans, their only contact with the health care system is for
preventive services, such as well child visits and annual physicals, services that establish long-standing relationships with health care providers before significant health care needs arise.
Although prevention-oriented services are firmly embedded in primary
care practice, many people believe health care providers should play an
even more active role in preventing disease and disability. Chronic conditions, such as heart disease, diabetes, and cancer, are increasingly common
and contribute to escalating health care costs. Many of these conditions are
influenced by modifiable lifestyle choices, amenable to behavioral interventions, and easier to treat if diagnosed early.
The most appealing answer to skyrocketing health care costs seems tantalizingly simple: reduce the underlying burden of disease. This
approach would keep people healthy, increase worker productivity, minimize service utilization, and reduce spending. Prevention has been a
cornerstone of the managed care movement since its inception, and preventive services continue to evolve and improve. Yet the promise of
prevention has never been fully realized, and some critics worry that
ineffective preventive services are only adding to, rather than reducing,
unnecessary service utilization.

WHAT ARE CLINICAL PREVENTIVE SERVICES?
Clinical preventive services are delivered to asymptomatic people in a
clinical setting by a health care professional. Such services can prevent
the onset of a disease process, detect risk factors that could lead to disease, or diagnose disease in its earliest stages before symptoms have surfaced. These services can be divided into three broad categories:
■ Immunization and preventive medicine involve the administration

of biological material or chemical compounds that serve to prevent
disease onset. Immunizations are the most common example of this
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type of preventive service. However, chemoprevention, such as the
regular use of aspirin in individuals at high risk for heart disease,
also represents a form of preventive medicine.
■ Disease screening includes a wide variety of screening tools, tests,

and techniques that detect disease or risk factors. Examples include
screenings for hearing impairment, blood glucose levels, and depression. Disease screens may, but do not necessarily, involve radiological imaging or laboratory testing. These clinical preventive services
promote early diagnosis because they are administered in a routine
manner to people who are not yet exhibiting disease symptoms.
■ Behavioral counseling interventions assist patients in adopting,

changing, or maintaining behaviors known to affect health outcomes or health status. Examples include smoking cessation and
dietary counseling.

Clinical
Preventive Services
Delivered to
individuals
in a clinical setting

Community
Preventive Services
Delivered to
populations through
community settings, such as
schools and workplaces

Some preventive services, such as invasive disease screenings like cervical
cancer tests, are only available in clinical settings. Other preventive services, such as behavioral counseling, are perhaps more available outside
the traditional health care provider practice than within. Some prevention
services are delivered collectively to large numbers of people and are commonly known as community prevention services. Community preventive
services can be delivered through health care systems; community settings,
such as schools and workplaces; or applied to entire communities in the
form of laws, regulation, or mass media campaigns. These community preventive services do not focus on individual patients. Although they might
involve the input of health care practitioners, they are not clinical in nature.
This paper focuses only on those services delivered by a health care provider or a member of the provider’s staff in a clinical setting.
Clinical preventive services are sometimes described as either “primary” or
“secondary” prevention. Primary prevention generally refers to services provided before a disease process has been initiated. Secondary prevention refers to services that seek to detect disease or disease risk factors early, before
physical symptoms are evident, to improve treatment effectiveness and reduce complications. In general, most forms of behavioral counseling, immunizations, and preventive medicine are seen as primary prevention, whereas
disease screenings are often viewed as secondary prevention.
The line between primary and secondary prevention can get blurry, however. Determining when abnormal biomedical markers represent a disease
state and how different diseases and symptoms relate to one another depends on the diagnostic criteria being used. These criteria are established
through professional consensus and can change as an improved understanding of the disease process develops. Distinctions between primary
and secondary prevention are likely to shift as disease models become more
nuanced, diagnostic technology becomes increasingly more sophisticated,
and the evidence base linking risk factors with disease grows.
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ROLE OF THE U.S. PREVENTIVE SERVICES
TASK FORCE
Scientific and technological advances have led to tremendous growth in
the range and type of clinical preventive services available. In the nottoo-distant past, the notion of a healthy person visiting the doctor would
have been inconceivable.1 Today, consumers are bombarded with advertisements for full-body scans and other types of diagnostic wizardry that
promise to detect physical problems they never even dreamed about. The
emerging science of genomics is likely to amplify this trend, opening a
universe of screening possibilities. Consumers and clinicians alike are
increasingly challenged to determine whether and under what circumstances these preventive services are necessary and appropriate and, conversely, when a service might be wasteful or even harmful.
Although preventive services may commonly be perceived as benign
interventions, they can pose very real threats, ranging from the rare
adverse reaction to vaccines to high false-positive rates from disease
screenings that trigger unnecessary and possibly harmful follow-up
testing and treatment interventions. Because preventive services are delivered to a large number of
healthy people, even adverse
Advisory Committee on Immunization Practices (ACIP)
outcomes that occur at relatively low rates could lead to a
The ACIP is composed of 15 experts in fields associated with immusubstantial amount of harm.
nization selected by the Secretary of the Department of Health and
The U.S. Preventive Services
Human Services (DHHS) to provide guidance on the most effective
Task Force (USPSTF) was estabways to circumvent vaccine-preventable diseases. The Committee
lished in 1984 to give health care
develops written recommendations for the routine administration
professionals advice about
of vaccines for both children and adults.
which forms of preventive care
should be routinely offered to asThe U.S. Preventive Services Task Force has archived its 1996 recomymptomatic patients. The origimendations related to childhood immunizations in recognition of the
nal USPSTF, empanelled by the
ACIP’s role in evaluating the clinical appropriateness of vaccines.
U.S. Public Health Service, consisted of 20 nonfederal experts.
These experts were charged with reviewing the scientific evidence for
specific clinical preventive services and making recommendations regarding which services should be a standard part of primary care practice.
Although its composition and methods have changed somewhat since
its founding, the USPSTF continues to identify the “gold standard” of
clinical preventive services that pass a rigorous, evidence-based assessment. A complete list of currently recommended services is provided in
an appendix to this paper. Resource and time constraints have precluded
the USPSTF from conducting an exhaustive review of all preventive services. Therefore, the USPSTF has identified specific services to assess
through a prioritization process that elicits input from a variety of stakeholders and considers the richness of the evidence base likely to be available to support decision making.
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The current USPSTF remains an independent body that is supported
through the Agency for Health care Research and Quality (AHRQ) and
receives research synthesis support through AHRQ’s network of Evidence-based Practice Centers (EPCs). The USPSTF conducts systematic
evidence reviews to determine whether a particular intervention has a
meaningful positive impact on health outcomes and whether these health
benefits outweigh any potential harm or adverse events the intervention could engender.2
The USPSTF does not conduct its own evaluative reThe USPSTF demands strong evidence
search; rather it relies on the existing evidence base to
develop its recommendations. The process the of benefits and has been cautious in
USPSTF uses clearly and explicitly acknowledges the weighing benefits against harm.
limitations, strengths, and weakness of this evidence
base. The quality of the evidence—the strength of both individual studies and the collective body of studies—is carefully considered and graded
as good, fair, or poor.
The USPSTF must frequently rely on multiple, unrelated studies to assess
the causal chain between the intervention, health benefit, and harm, and it
has developed a methodical approach to making these linkages. The most
rigorous research design for establishing the effectiveness of interventions,
randomized clinical trials (RCTs), often has not been applied to clinical
preventive services. When RCTs of preventive services have been conducted,
the study time frame is often too short to establish long-term preventive
health benefits. Therefore, the USPSTF typically examines separate studies
and determines if the studies fit together in a logical, rational manner.
For example, the USPSTF considered good evidence from RCTs that smoking cessation counseling combined with nicotine replacement therapy is
effective in reducing smoking rates. However, these studies did not look
longitudinally to assess the impact smoking cessation had on health outcomes. In this case, the USPSTF considered separate studies that provided
good evidence that smoking cessation led to decreased rates of heart disease, lung cancer, and stroke. Balancing this evidence against evidence of
potential harm, the USPSTF concluded that clinicians should screen all
adults for tobacco use and offer cessation counseling to those who use
tobacco products.
The USPSTF has set a high bar in demanding strong evidence of benefits
and has been cautious in weighing benefits against harm. In many instances,
it has concluded that the available evidence is insufficient to recommend
either for or against a particular intervention. In others, the recommendation is narrowly focused on particular high-risk populations for whom the
benefits of the intervention clearly outweigh the possible harm.
The USPSTF’s recommendations involve some degree of value judgment
and expert opinion.3 Reconciling conflicting pieces of evidence, assessing
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the magnitude of health benefits and harms, and weighing benefits against
harms (particularly if the evidence related to harm is weak) can represent
difficult decisions. Although value judgments are inherent in the assessment of the evidence, the USPSTF’s process is firmly grounded in the
evidence base and explicit decision rules have been established.
The USPSTF acknowledges that factors unrelated to the scientific evidence,
such as practical considerations, liability concerns, and individual clinical circumstances, may lead clinicians to provide preventive services that
the USPSTF does not broadly recommend due to insufficient evidence.
Clinicians confronting the practical reality of patients who could be spared
significant suffering through the use of a preventive service do not have
the luxury of waiting until more evidence becomes available. Other panels and advisory bodies, such as physician specialty societies, may make
recommendations based on expert opinion in the absence of a strong evidence base in order to help providers with this difficult clinical decision
making. When the USPSTF’s recommendations differ from other expert
panels and advisory bodies, these differences are identified and discussed.
The USPSTF also includes clinical considerations in all their recommendation statements to help clinicians navigate the difficult decisions they
are likely to encounter.
For example, the USPSTF found that the evidence is insufficient to recommend for or against the routine screening of pregnant women for
gestational diabetes. The American Diabetes Association recommends
screening all women at risk for gestational diabetes, including all women
who are older than 25, are overweight, are members of a high-risk ethnic group, have a family or personal history of glucose intolerance, or
have had a prior poor obstetrical outcome.4 The American College of
Obstetricians and Gynecologists (ACOG) recommends a similar riskbased approach, but notes that because only a small percentage of patients would be deemed low risk using these criteria, universal screening may be a more practical approach.5
Perhaps one of the most compelling practical issues that must be considered in assessing preventive services is cost. The USPSTF’s methods for
incorporating economic costs into its assessments continue to evolve.6
When the USPSTF was first established, it explicitly excluded cost
considerations from its evaluative process. As methods to assess costeffectiveness have become more sophisticated and policymakers and purchasers have clamored for cost-saving approaches to care, information
about costs is increasingly factored into the USPSTF’s deliberations. To
the extent sound information is available, the USPSTF now considers the
total economic costs that result from a preventive service, but costs are
not the driving priority. When the USPSTF considers economic factors,
those analyses are summarized in its recommendation statements.7
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IS AN OUNCE OF PREVENTION
WORTH A POUND OF CURE?
Preventive services are often heralded as a way to reduce spending for
health care services, but this may be a simplistic and unrealistic standard.
With the exception of some immunizations, most preventive services do
not “save” money. There is a net cost associated with most preventive
services because (a) significant costs are involved in delivering the intervention to a large, asymptomatic population from whom only a fraction
would have required treatment had the intervention not been delivered
and (b) many preventive services do not obviate the need for some form
of health care treatment, although they may initiate treatment at a stage
when the disease is easier and cheaper to treat. However, these treatment
savings generally are not large enough to offset the costs associated with
delivering the intervention to a broad population.
But this simple view of cost saving does not adequately capture the superior health care benefits derived from effective clinical preventive services.
A more useful approach may be to consider the cost effectiveness of preventive interventions. Cost-effectiveness analyses seek to measure the value
of a given intervention in terms of a ratio of net costs relative to the outcome achieved, that is, the net health benefit.8 Net costs include the costs of
implementing the intervention, plus any costs related to treating the unintentional harm or side effects resulting from the intervention, minus the
costs averted because of the intervention. Some analyses may include “costs
avoided” beyond those that would be incurred in a health care setting,
such as the costs an employer might avoid because the service prevented
an employee from taking sick leave. Other analyses are more narrowly
focused on health treatment costs, making it important to understand the
perspectives being used in any comparison of cost-effectiveness measures.

Cost Effectiveness
Net Costs
Net Health
Benefit

=

$
QALY saved or
life year saved

Similarly, different cost-effectiveness analyses may use different metrics
to gauge health outcomes or benfits. Health outcomes are frequently measured as life years saved or quality-adjusted life years (QALY) saved in
order to facilitate comparisons across different types of interventions. Analyzing these outcomes for a population requires both an understanding of
the long-term impact of the preventive service in reducing mortality and
morbidity and a sense of the prevalence of the disease the service seeks to
prevent (or likely prevalence if the service were not widely available).
Cost-benefit analyses pursue a similar approach but assign monetary value
to the health outcomes achieved in order to allow for a more direct financial comparison. As a general rule of thumb, $75,000 is commonly used as
a benchmark for valuing for each QALY saved. Services with a costeffectiveness ratio below $75,000 per QALY saved (or a cost-benefit ratio of
less than one) would be viewed as “worth it” from a purely financial perspective using this benchmark. Obviously, setting such a benchmark is
fraught with subjectivity and can be problematic in a health policy context,
given understandable uneasiness in assigning dollar values to human life
and suffering.
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Even using a more conservative standard for valuing a quality year of
life, most preventive services recommended by the USPSTF would be
deemed cost effective. For a relatively small net cost, these recommended
services produce valuable health outcomes. A recent analysis of preventive services9 calculated the following estimates of cost effectiveness:

Evidence does not
equal certainty.

■ Pneumococcal vaccine for adults over 65 years old: cost saving

(that is, less than $0/QALY saved)
■ Tobacco cessation counseling: likely cost saving to $2,000/QALY saved
■ Chlamydia screening for women 15–24 years old: $2,500/QALY saved
■ Colorectal cancer screening for people more than 50 years old:

$13,000/QALY saved
These examples showcase some of the clearest “good buys” in clinical
preventive services.
The cost effectiveness of other services, particularly many behavioral counseling services, is harder to quantify. Efforts to estimate the cost-effectiveness
of these services have been hampered by uncertainty related to a number
of issues, including the long-term adherence to behavioral changes brought
about by counseling services and heterogeneity in the nature of the services offered. For example, estimates of the cost effectiveness of screening
to identify problem drinking followed by brief counseling can range from
cost saving to over $150,000 per QALY saved. The magnitude of this range
is due to a lack of precision regarding a number of variables, including the
cost of providing the screen, the long-term impact of the intervention on
reduction of alcohol consumption, the prevalence of problem drinking in
the population, the duration of morbidity resulting from problem drinking, the costs of care resulting from that morbidity, and the mortality associated with problem drinking.10
As the availability of sound cost-effectiveness analyses grows, the USPSTF
is seeking to incorporate this information into its recommendations. In many
cases, the USPSTF is directly sponsoring these analyses to better inform its
decision-making processes. Although the role of cost information has not
been fully resolved, the USPSTF is unlikely to evaluate the cost effectiveness of a preventive service relative to a treatment-only scenario. Rather,
cost effectiveness analyses will likely be used to help determine when, how
often, and to whom particular services should be delivered.
For example, a cost effectiveness analysis of cervical cancer screening
found that a Pap test given every three years saved 97 percent of the lives
that would have been saved by an annual screening and reduced costs by
67 percent.11 While the USPSTF’s recommendation to provide cervical
cancer screening at least every three years hinged on the health outcomes
achieved with this testing frequency, in the future “closer calls” could be
informed more directly by cost considerations.
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Cost-effectiveness analyses can also help differentiate between services
or screening tests targeted at the same disease or risk factor. Often, newer
technologies offer superior screening tools, such as fewer false negatives
or false positives, but these tests may be far more expensive than the older
screening techniques. Rigorous cost-effectiveness analyses can help determine whether the health benefits of the newer technologies justify the
additional expense.

INSURANCE COVERAGE POLICIES
In the past, concerns about cost have made insurers and purchasers cautious about including a wide range of clinical preventive services in health
benefit packages, but these attitudes are changing. Insurance coverage
for clinical preventive services has improved significantly over the last
several decades, but lack of coverage or inadequate reimbursement for
some services continues to be a barrier to increased delivery. Some types
of preventive services, such as immunizations and annual physicals, are
now commonly covered, but coverage for other services, particularly behavioral counseling services, remains the exception rather than the rule.

Private Health Insurance
Employer-sponsored health plans generally do provide coverage for services such as annual physical or gynecological exams, breast cancer
screening, and childhood immunizations. Coverage for adult vaccines
and other types of screening services, such as colorectal cancer screening and chlamydia screening, is more variable. Coverage for lifestyle
modification counseling, like weight loss and alcohol abuse, is relatively
uncommon.12 Although many large employers specifically negotiate with
health plans to ensure the coverage of preventive services, medium and
small employers are less likely to demand these specific benefits from
health plans.13
Coverage for preventive services can differ significantly across insurance
plans (Table 1, see next page). Historically, managed care plans have offered more generous preventive benefits than fee-for-service plans. However, traditional health insurance plans have also begun covering more
preventive benefits, perhaps in an effort to attract the healthy people to
whom preventive services appeal.
Improved coverage for clinical preventive services has been aided by the
inclusion of prevention-related indicators in performance measurement
efforts, such as the accreditation of health plans by the National Committee for Quality Assurance (NCQA). The extent to which accreditation incentives have influenced plans to broadly include recommended
clinical preventive services in their benefit packages appears somewhat
limited. Only 10 preventive services are included in current NCQA quality indicators, and only one of these, smoking cessation assistance, is a
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TABLE 1
Percentage of Plans Providing Coverage for Selected Preventive
Services in Employer-Sponsored Insurance by Plan Type
PREVENTIVE SERVICE

Coverage
in PPO

Coverage
in HMO

Coverage
in POS

Physical exam

80%

84%

78%

Childhood immunizations

79

80

78

Influenza vaccine

57

66

58

Cholesterol screening

64

66

53

Breast cancer screening

90

91

80

Colorectal cancer screening

77

73

66

Weight loss counseling

16

21

13

Alcohol abuse prevention/identification

23

22

15

Source: Partnership for Prevention analysis of Mercer National Employer Survey; and M. A. Bondi et al.,
“Employer Coverage of Clinical Preventive Services in the United States,” American Journal of Health
Promotion, publication pending.

behavioral counseling service. Furthermore, the relation between performance on these indicators and employer or consumer selection of health
plans is not well established.
State insurance mandates may also contribute to improved coverage
for specific preventive services. A recent study of state mandates conducted by Partnership for Prevention, however, found that the majority
of states do not require health plans to cover a broad array of preventive services.14 Services such as mammography and childhood immunizations were more likely to be subject to mandates than lifestyle-related
behavioral counseling services.
States rarely tie their mandates explicitly to USPSTF recommendations,
and many states lack mandates for recommended services. For example,
only 15 states identify colorectal cancer screening as a required benefit,
although this screening is strongly recommended by the USPSTF. States
also require coverage of some services that are not recommended by the
USPSTF. Prostate cancer screening benefits are required in 27 states, but
the USPSTF concluded that the evidence base was insufficient to recommend either for or against this service. Furthermore, because self-insured
plans, typically offered by large employers, are exempted from state mandates through the Employee Retirement and Income Security Act (ERISA)
of 1974, the extent to which state mandates influence the availability of
preventive benefits is unclear.
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Medicare
Coverage of preventive services under Medicare has historically required
explicit congressional authorization. The program’s original authorization established that Medicare would only pay for services that were
medically necessary to diagnose or treat “illness or injury or to improve
the functioning of a malformed body member.”15 This statutory language
has historically been interpreted to mean that an act of Congress is
necessary to add any and all preventive benefits to the fee-for-service
Medicare program.
Proposals to add specific preventive services have often faced Medicare’s preventive services
uphill political battles. A bill to cover Pap tests under Medicare
policies do not completely match
was introduced annually for 15 years before it was enacted in
1989.16 Such proposals have often been subjected to a budget USPSTF recommendations.
neutrality test, meaning that proposed increases in Medicare spending need
to be offset by spending reductions or revenue increases. Because many
services are not cost saving in the strictest sense, this requirement has stalled
efforts to expand the preventive services benefit package. Although cost
constraints have been an important political barrier, other factors make
passage of these proposals difficult. Disease-specific expansions of preventive benefits are frequently viewed as low-priority items on the legislative
agenda and are likely to get overshadowed by broader policy issues.
Despite these challenges, a number of preventive benefits have been added
over the years. The Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003 recently expanded preventive service offerings even further.17 MMA provided for a “welcome to Medicare” physical
examination and authorized blood tests to screen for cardiovascular problems and diabetes as general benefits.
These additions have not always harmonized with USPSTF recommendations. For example, in order to receive reimbursement for the “welcome”
visit, physicians must provide an electrocardiogram. Although this requirement was included in the MMA’s statutory language, it is not recommended
by the USPSTF. The USPSTF recommends against routine electrocardiograms
in adults at low risk for coronary heart disease and found that the evidence
was insufficient to recommend such screening among adults at risk for
coronary heart disease. Conversely, Medicare does not currently cover some
preventive services recommended by the USPSTF, including screening for
depression and alcohol misuse. Table 2 (see next page) provides a summary of preventive service benefits currently offered through Medicare.
Medicare managed care plans (formerly known as Medicare+Choice plans,
and now known as Medicare Advantage plans) must cover all preventive
benefits specifically authorized by Congress but can add additional services at their discretion. When managed care plans were first offered to
Medicare beneficiaries under the Medicare+Choice program, people who
selected the managed care options typically enjoyed broader coverage
Continued on page 13 ➤
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TABLE 2
Medicare-Covered Preventive Services
PREVENTIVE SERVICE

COVERED POPULATION

FREQUENCY OF COVERAGE

COST SHARING

Hepatitis B vaccine

People at medium- to high-risk
for hepatitis B

Series of three

Copayment
after deductible

Influenza vaccination

All

Once every flu season

None

Pneumococcal
vaccination

All

Once (additional shots covered
based on risk)

None

Bone mass
measurements

People at risk for osteoporosis

Every 24 months, or more frequently
if medically necessary

Copayment
after deductible

Cardiovascular
screening blood tests

Ordered by clinicians for
asymptomatic beneficiaries

Every 5 years

None

Diabetes screening tests

People at risk for diabetes or
people who have been diagnosed
with pre-diabetes

Every 12 months for individuals who
have never been tested and were not
diagnosed with pre-diabetes, or every
6 months for individuals diagnosed
with pre-diabetes

None

Diabetes outpatient
self-management training

People at risk for complications
from diabetes

As medically necessary

Copayment
after deductible

Colorectal cancer
screening tests

All age 50 and older

Fetal occult blood test – every 12 months

No minimum age for colonoscopy

Flexible sigmoidoscopy – every 4 years

Copayment
after deductible

Colonoscopy – every 10 years
(every 2 years for those at high risk
for colorectal cancer)
Barium enema – every 4 years as a
substitute for the flexible sigmoidoscopy, or every 2 years as a substitute
for colonoscopy for those at high risk
for colorectal cancer
Prostate cancer
screening tests

Men over age 50

Every 12 months

Copayment
after deductible

Screening mammography

Women age 40 and older

Every 12 months
(women between ages 35 and 39 are
eligible for one baseline mammogram)

Copayment
no deductible

Screening Pap smear and
pelvic examinations

Women

Every 24 months
(every 12 months for women at high
risk for cervical or vaginal cancer)

Copayment
no deductible

Screening for glaucoma

People at risk for glaucoma

Every 12 months

Copayment
after deductible

Sources: Partnership for Prevention, “Medicare Covered Preventive Services,” www.prevent.org/publications/INFORMATION_sheet.pdf; Janet Heinrich,
Government Accountability Office, “Medicare Preventive Services: Most Beneficiaries Receive Some but Not All Recommended Services,” GAO-04-1004T,
testimony before the Subcommittee on Health, Committee on Energy and Commerce, U.S. House of Representatives, September 2004, available at www.gao.gov/
new.items/d041004t.pdf; and Centers for Medicare and Medicaid Services, “Medicare Preventive Services: Expanded Benefits,” May 2005, available at
www.cms.hhs.gov/medlearn/expanded_benefits_06-08-05.pdf

National Health Policy Forum | www.nhpf.org

12

Issue Brief – No.806
August 24, 2005

➤ Continued from page 11

for preventive services and had lower cost-sharing requirements for
those services relative to fee-for-service beneficiaries. However, many
Medicare+Choice plans exited the market, and many of the ones that
remained reduced their coverage and increased their cost-sharing
requirements.18 The preventive services currently offered through Medicare Advantage plans have not been collectively documented, therefore
it is difficult to know whether beneficiaries now enrolled in managed
care plans have access to a broader array of preventive services than
those mandated by Congress.

Medicaid
Medicaid policies regarding clinical preventive services for children are
governed by federally mandated coverage for Early and Periodic Screening, Diagnosis, and Treatment (EPSDT). This mandated benefit includes
“necessary health care, diagnostic services, treatment, and other measures
to correct or ameliorate defects and physical and mental illnesses and conditions discovered by the screening services, whether or not such services
are covered under the state plan.” Providers and patients have complained
that unless a service is explicitly identified in the state’s Medicaid plan,
reimbursement may not be available. Because the mandate is so broadly
defined, state interpretations of which
services fall under this mandate have
ACIP-Recommended Vaccines
varied, federal oversight has been difficult, and state EPSDT policy has ofChild
Adult
ten been the subject of litigation.
■ Hepatitis B
■ Tetanus-diptheria
Although Medicaid coverage for
(every 10 years)
■ Diptheria-tetanusbroadly defined preventive services
■ Influenza
acellular pertussis
for children is difficult to characterize,
(yearly for adults over 50
coverage for childhood immuniza■ Haemophilus influenzae
and health care workers)
tions is relatively clear and uniform.
■ Inactivated poliovirus
Childhood vaccines are centrally man■ Pneumococcal
■ Pneumococcal conjugate
aged through the federal Vaccines for
(adults over 65)
Children (VFC) program, which pur■ Measles-mumps-rubella
■ Hepatitis B
chases vaccines for Medicaid benefi(at risk adults and
■ Varicella
ciaries, uninsured children, and
health care workers)
underinsured children who receive
■ Hepatitis A
■ Measles-mumps-rubella
services at community health centers.
■ Influenza
(susceptible adults)
The Advisory Committee on Immunization Practices (ACIP) establishes
■ Pneumococcal
■ Varicella
a list of vaccines for the VFC Program,
polysaccharide
(susceptible adults)
along with schedules regarding the
■ Meningococcal conjugate
appropriate periodicity, dosage, and
(adolescents)
contraindications applicable to pediatric vaccines.

Source: www.cdc.gov/nip/recs/child-schedule.htm; www.cdc.gov/nip/recs/adult-schedule.htm
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As a practical matter, the USPSTF has recommended relatively few preventive services for children beyond childhood immunizations; they
include oral fluoride supplementation, newborn testing for congenital hypothyroidism and phenylketouronics, lead screening, vision screening, and
ocular medication for newborns to prevent gonorrhea. The existing evidence base is insufficient to allow the USPSTF to make a recommendation
either for or against many of the preventive services that advocates believe
should be incorporated into primary care for children, such as screening
for depression, counseling to prevent and address obesity, and tobacco use
prevention counseling.
A comprehensive review of state Medicaid policy regarding A comprehensive review of
specific clinical preventive services for adults is not currently
Medicaid’s clinical preventive
available. It appears that coverage of adult preventive services
varies significantly across states. Although 24 states and terri- services policies is not available.
tories have elected to offer diagnostic, screening, and preventive services
as an optional benefit, many limit coverage to diagnostic or screening
services, and the specific tests and services covered under this option are
at the states’ discretion.19 At the same time, states that have not elected to
cover this optional benefit may cover specific clinical preventive services
through the physician service benefit. A recent study of Medicaid immunization coverage policies for noninstitutionalized adults found that although 48 states provided some level of adult immunization coverage,
only 32 covered all the immunizations recommended by ACIP and most
require significant cost sharing.20
Medicaid managed care plans have the latitude to cover preventive services not normally offered through the state’s traditional Medicaid program. States can also identify specific preventive services that must be
covered by plans through contractual agreements. For example, 32 of the
48 states with contractual agreements for managed care or primary care
case management explicitly cover HIV testing and counseling.21 Although
such contractual specifications do not guarantee service delivery, they do
provide assurances that providers will be reimbursed for these services.

The Uninsured
Expansions in clinical preventive service benefits do little to improve access to those services for the more than 40 million Americans who do not
have health insurance. The uninsured use these services at much lower
rates than insured populations; insurance status is perhaps the single best
predictor of preventive service use.
Some level of access to preventive care is provided through federally
funded health centers and other safety net providers. Direct funding for a
limited number of cancer screenings is provided through the National
Breast and Cervical Cancer Early Detection Program at the Centers for
Disease Control and Prevention (CDC). The program funds states who,
in turn, work with community-based partners to provide clinical breast
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exams, mammography, Pap tests, surgical consults, and more definitive
diagnostic testing, when needed, to uninsured or underinsured women.
The program received $204 million in fiscal year (FY) 2005 appropriations. Similarly the Section 317 immunization program provides funding
to states for vaccines for uninsured adult and underinsured children, while
VFC funds vaccines for uninsured children. The Section 317 program received $479 million in FY 2005 appropriations.

PRACTICING WHAT IS PREACHED
Despite efforts to improve the evidence base and increase insurance coverage for clinical preventive services, the usage rates for many recommended services are unacceptably low, and, at the same time, ineffective
services continue to be delivered. About 20 percent of preschool children
have not been properly immunized.22 Approximately 37 percent of Medicare beneficiaries have never received a pneumococcal vaccine and about
30 percent did not receive their annual influenza vaccine.23 Only 33 percent
of adults over the age of 50 have been screened for colorectal cancer.24
Available data suggest that adherence rates for behavioral counseling interventions are even lower than those for disease screenings, immunizations, and chemoprevention.25 Vulnerable populations, including racial and
ethnic minorities, the poor, and persons with limited education or English
proficiency, are the least likely to have used recommended preventive services of all types.26
The reasons for this gap between what the evi- Use rates for many recommended services
dence base suggests and current medical practice
are varied and complex. Despite insurance expan- are low, particularly among poor, minorsions, payment concerns continue to play some
ity, and other vulnerable populations.
role in discouraging providers from offering clinical preventive services. Lack of coverage for many services (particularly
counseling services), low reimbursement rates for covered services, high
patient deductibles, and unclear billing protocols may make preventive
services unappealing to some providers.
Factors beyond financial incentives also play an important role in the uptake of preventive services. Even when such services are well covered
through insurance, adherence to evidence-based standards can be disappointing. Simply put, providers are often unaware of what preventive services should be delivered, or they lack the systems and processes necessary to ensure that these services are incorporated into primary care. In
some cases, particularly for counseling services, providers may not see the
provision of preventive services as their role.27 They may be skeptical about
patients’ willingness to change behaviors,28 may lack confidence in their
own skills to support behavioral change, and may be uneasy about the
impact such counseling could have on their relationships with patients.
Providers face a number of competing demands in organizing their patient
care encounters. Visit times are short and are often focused on addressing
the problem or complaint that led the patient to initiate the medical en-
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counter. The average adult patient has about a dozen risk factors, requiring
approximately 24 of the USPSTF’s recommended clinical preventive services.29 It would be difficult to accommodate all of these services in a single
wellness-oriented visit. Furthermore, several of the recommended services,
including mammography and colonoscopy, are not directly provided by
primary care practitioners and would require
referrals to different types of clinical providers. Fundamental

changes in care delivery, such as electronic health records,
may be necessary to increase use of
preventive services.

Incorporating a comprehensive set of recommended
preventive services into primary care practice is clearly
challenging, but some providers appear better-prepared
to tackle this challenge than others. A recent study sought
to identify those characteristics of physician practice that were associated
with the delivery of diabetic monitoring, cancer screening, and vaccinations. The characteristics associated with higher use of the services studied included practicing in a group with three or more physicians, being
board certified, graduating from a medical school in the United States or
Canada, and having a low proportion of total practice revenue derived
from Medicaid.30

Heavy reliance on Medicaid as a payer (and presumably a high proportion of Medicaid patients) appears to be associated with lower uptake of
preventive services for physicians in private practice; however, it is not
clear that this association holds for other types of safety net providers. A
separate study found that community health center patients were no less
likely to receive preventive services than the average patient receiving
care from a private physician.31
The attitudes, competency, and knowledge base of individual providers
may influence whether preventive services are delivered, but systematic
changes are likely needed to substantially improve uptake rates. Organizational changes that fundamentally alter the way care is delivered, such
as standing orders are among the most powerful interventions that can
be taken to boost preventive service use rates. Efforts to give providers
retrospective feedback regarding their compliance with preventive service recommendations have proven less effective than point-of-service
interventions. Electronic health records, including point-of-service provider reminders and a team-based approach to care are often cited as
important structural changes that must occur if preventive services are to
be more widely delivered.
Retooling the care delivery process to better support prevention is necessary, but ideally such efforts would also be centered on the needs of patients. Even strongly motivated providers may face patient resistance to
the use of preventive services. Financial concerns, as well as attitudes
and beliefs, may make patients reluctant to use the preventive services
offered to them. Consumers may be unaware of the benefits of such services, or they might undervalue those benefits if faced with out-of-pocket
expenses in order to take advantage of them. Patient financial incentives
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are known to have a significant impact on preventive service use. For
example, seniors lacking supplemental insurance to cover their Medicare
cost-sharing obligations were 10 percent less likely to have received cholesterol screening, mammography, or Pap tests, relative to those patients
with supplemental coverage.32
Consumer-driven health care coverage models, such as health spending accounts in conjunction with high-deductible insurance plans, may
further underscore the need to consider individuals’ knowledge and
understanding about the relative value of preventive services. As such
coverage models become more common, concerns have been raised that
preventive service use rates could be undermined if such services are
not exempted from the deductible. Some high-deductible plans do provide “first dollar” coverage for preventive care to encourage beneficiaries to use these services.
Increased consumer control over benefits provides greater freedom for
patients to decide what services are most appropriate for them in light of
their individual circumstances. Consumers are arguably most in touch
with their own risks, values, concerns, and preferences and are in the best
position to determine which evidence-based preventive services meet their
needs. Critics question whether patients will be armed with adequate
information to make good decisions. For instance, consumers might bypass beneficial services if they are not sufficiently aware of the value of
these services, or they could utilize unnecessary—and potentially harmful—services if swayed by the marketing pitches of opportunistic providers. Advocates and critics of consumer-driven plans agree that good
information will be needed to help people make health care decisions
and that it will be a challenge to ensure that information keeps pace with
rapid technological advances.

POLICY IMPLICATIONS
Policymakers hoping to leverage the potential of preventive services face
a number of challenges. These challenges can be summarized as they pertain to particular policy questions.

Should additional public funds be used
to improve the evidence base?
Employers, insurers, providers, and consumers all require guidance in
determining who should have access to which services and when these
services should be provided. Bad decisions in this regard affect both private and public spending on health care services. Despite substantial
progress in recent years, the evidence base related to clinical preventive
services is not yet robust. The USPSTF has considered 52 services on which
recommendations could not be made due to insufficient evidence either
for or against the service. These services relate to a wide range of health
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conditions, such as obesity, cardiovascular disease, and suicide, all of
which place a tremendous burden of disease on society. The USPSTF has
clearly identified research gaps in its recommendation statements.
The evidence base for counseling-related services is particularly weak.
This weakness reflects the difficulty of assessing these types of interventions due to inconsistent delivery methods, the long time horizon typically associated with behavioral change and health outcomes, and the
lack of a clear market incentive for private sector investment in such interventions. Pharmaceutical and device manufacturers can
market disease-screening tools and chemopreventive The evidence base for clinical preagents and invest in RCTs in order to gain FDA approval
ventive services is growing, but it
for these products. Similar financial incentives generally
do not exist for counseling services, leading to little pri- needs further improvement.
vate sector support for such studies.
The evidence base for disease screenings and preventive agents is far
from ideal, however. Effectiveness studies on these products often focus solely on whether the test accurately diagnoses a particular condition or whether the chemical or biological agent prevents a particular
disease. These studies are not likely to evaluate whether broad-based
implementation of the intervention will result in a meaningful difference in health outcomes for a population.
Policymakers are left to consider the role of public sector financing to fill
these holes in the evidence base to both avoid inappropriate utilization of
needless preventive services and encourage use of valuable services. Private
sector purchasers of health insurance also have an interest in assessing the
appropriateness of preventive services. However, these parties may have a
short-term perspective in determining the value of an intervention’s impact,
may not have sufficient resources to conduct an evaluative study independently, or may be reluctant to fund and publish work that would also benefit
competitors. Ongoing collaboration with private sector interests will likely
be needed to identify opportunities for publicly convened, but potentially
co-funded, studies of clinical preventive service effectiveness.

How should health insurance coverage policies
reflect the existing and emerging evidence base?
Once an evidence base for a particular service is established, both public
and private insurers must decide whether and how to harmonize their coverage policies with these findings. Policymakers should consider how well
the evidence regarding preventive services is made available to private
sector insurers and examine the mechanisms through which this evidence
is incorporated into the coverage policies of public insurance programs.
Critics have long argued that relying on congressional approval for each
and every preventive service benefit under the Medicare program is
imprudent, given the rapid proliferation of new interventions and the
expanding evidence base related to these services. These critics maintain that a more streamlined process, such as a general approval for all
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services recommended by the USPSTF or the creation of an administrative process for modifying preventive coverage, should be put in place.
Others believe that private, market-based organizations are best suited
to design benefit packages that meet consumers’ needs and advocate for
expanded reliance on Medicare and Medicaid managed care plans to fill
this need. Whether the service in question is preventive or therapeutic,
some policymakers contend that private plans are better equipped than a
government bureaucracy to develop coverage decisions that are in line
with the scientific evidence and free from political interference. However,
the majority of Medicare beneficiaries are enrolled in the traditional program, so congressional interest in the evolution of clinical preventive services and the evidence base regarding these services will likely be needed
for the foreseeable future.
At the same time, opportunities exist to assess the merit of preventive services that are covered through Medicare and Medicaid but are not yet
supported by the existing evidence base. The new preventive benefits established for Medicare beneficiaries under the MMA were intended to
improve the health and well being of beneficiaries, but the effect these services will have on health outcomes is unclear. The “welcome to Medicare”
physical examinations delivered to new Medicare beneficiaries are likely
to vary in content, comprehensiveness, and quality of follow-up services.
Exploring the implications of this variation could provide important information regarding the best way to provide preventive services to seniors.
Private health plans serving both the publicly and privately insured will
need assistance in keeping abreast of the evolving evidence base, as will
employers and state-based purchasers. Private sector organizations, such
as the National Business Group on Health, have collaborated with federal
agencies to help purchasers pursue an evidence-based approach to health
benefits design. Opportunities may exist to amplify efforts such as these.

In what way should providers be supported
to implement evidence-based practices?
Federal activities have historically supported the dissemination and
adoption of best practices related to preventive care, and some argue
that these efforts should be strengthened. The USPSTF was originally
convened to synthesize the available evidence to help providers make
sound clinical decisions. Since its inception, the USPSTF has looked for
ways to make this information more readily available to practicing clinicians. AHRQ’s Prevention Dissemination and Implementation (PDI)
program (formerly known as Put Prevention into Practice) seeks to
distribute USPSTF findings through multiple communication vehicles.
PDI has developed Web-based tools, interactive search engines, PDAbased software, and listserv notices as means to broadcast updates of
recommendations. A new pocket guide of USPSTF recommendations is
available to order or download.33 The program also provides clinicians
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with tools and guidance to address the barriers that can impede the
delivery of recommended services.
A variety of other government-sponsored efforts to increase both provider awareness and use of preventive services have been attempted.
They include efforts by the Quality Improvement Organizations (QIOs)
created by Centers for Medicare & Medicaid Services (CMS), as well as
programming provided through the CDC, and the Health Resources and
Services Administration (HRSA).
Some would argue that additional resources are needed to bring these
activities up to scale and to allow for more active outreach to clinicians.
Additional research on the barriers facing physicians and the most effective ways to overcome these hurdles has been suggested. Others have
expressed concerns that targeted efforts to change preventive service
practices could never achieve the critical mass necessary to ensure widespread dissemination and only contribute to the information overload
and fragmentation experienced by clinicians. These observers call for a
more integrated approach to improving the quality of primary care.
Broader policy efforts related to a national health information infrastructure, pay-for-performance initiatives, and medical education clearly have
the potential to influence the delivery of preventive services. Federal funding and support for the development of information systems, revised
educational expectations, revamped clinical processes, improved caremanagement techniques, and rigorous performance measurement may
have an even greater influence on prevention-oriented care than those
activities specifically directed at the uptake of clinical preventive services.
In light of the systemic failings that undermine preventive care, policy
initiatives that address these fundamental dysfunctions in the delivery
system appear necessary for preventive and treatment practices alike.
Shifting health care providers’ focus to
health rather than disease is widely espoused as a critical dimension of highquality primary care, but some believe
that this goal is not realistic given the very
nature of medical science, training, and
financing. Those holding this perspective
are skeptical that medical practice can
adapt to the demands of wellness-centered care and advocate policies that
look beyond the traditional biomedical,
clinical model. The ambivalence with
which many health care providers view
their role in prevention, particularly in
offering behavioral counseling, lends
credence to this perspective. Others
counter that no alternative infrastructure
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Evaluating Alternatives to Clinical Prevention
CMS is designing a demonstration project, called the Senior
Risk Reduction Program, which would use a variety of questionnaire-based risk assessment tools to screen fee-for-service
beneficiaries for health risks, gauge use of preventive services,
and refer beneficiaries to nonclinical settings for lifestyle modification and other support services. The project would test
different methods for assessing risks and providing preventive services in home and community settings, including peer
support groups and self-management tools. Although planned
for some time now, the demonstration design has not yet been
finalized and is awaiting clearance by the Department of
Health and Human Services and the Office of Management
and Budget.
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is sufficiently developed and deployed to assume the preventive roles
health care clinicians are now being asked to play. Although many acknowledge the shortcomings of medical practice, addressing these problems is often seen as a more viable approach than creating nonclinical
alternatives like community- or worksite-based services. In reality, broadscale uptake of preventive services may need to rely on multiple delivery
mechanisms, including both clinical and nonclinical settings.

What type of information will assist
consumers in making appropriate choices?
Although health policy debate has often focused on ways to improve the
effectiveness and efficiency of health care providers, there is a growing
recognition that consumers can play a pivotal role in shaping the care
they receive. This understanding is perhaps most evident in the growing
visibility of consumer-directed health insurance models, but it is also affecting more traditional approaches to health care financing and delivery. Actively engaging patients in their own care management has been
shown to improve compliance as well as outcomes for both preventive
and therapeutic interventions.
Consumer values, attitudes, and beliefs have long Prevention may need to rely on multiple
played a particularly strong role in the uptake of
preventive services, considering these services have delivery mechanisms, including clinical
often required out-of-pocket outlays. In many and nonclinical settings.
ways, an examination of preventive service use
could provide a useful window into a future driven increasingly by individual decision making and financial risk. The history of preventive services suggests that consumers do not always make decisions in alignment with their long-term health interests. The reasons for this “flawed”
decision making are complex; consumers may lack complete information, may be unable to navigate the complexities of the information presented, or may place a higher value on other priorities or concerns.
Individuals’ care-seeking behavior is often not as rational as health
economists would like to imagine. Decisions are frequently mediated
by emotional responses, such as fears that may be disproportionate to
actual risks, trust in professional and familial care givers, and expectations regarding quality of life and longevity, all of which have deep cultural, and sometimes religious, roots. The influence of these motivators
is not fully understood, and important differences between racial, ethnic, and socio-economic groups have not been adequately explored.
Additional research is needed to determine how consumers access and
use information in choosing preventive services and to measure the extent to which other factors, such as competing needs and personal values, influence these decisions. Findings from such research could aid in
the development of consumer-oriented interventions to increase use of
appropriate services and decrease use of unnecessary services.
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CONCLUSION
The vision of a true health care system remains a compelling, but elusive,
goal. Moving toward that goal will require improved scientific evidence
regarding how best to prevent disease and disability, as well as a more
nuanced understanding of how to motivate employers, insurers, providers, and consumers to act in a manner consistent with that evidence base.
In the short term, budgetary constraints may require policymakers to choose
between expanding the evidence base related to the value of preventive
services and improving the implementation of prevention-oriented interventions known to be highly valuable.
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Adults: B
Adults at increased risk: A
Pregnant women: A
Women at increased risk of breast cancer
and decreased risk of adverse events: B
Women ages 40+: B
Women after child birth: B
Women younger than age 65 who are
sexually active and have a cervix: A

Increased risk women: A
Pregnant women at increased risk
and age 25 and younger: B
Adults ages 50+: A
Preschool children, using oral fluoride
supplementation in specific areas whose
water is deficient in fluoride: B
Adults within a system of care: B
Adults with hypertension or dyslipidemia: B

Screening for alcohol misuse

Aspirin for primary prevention of cardiovascular events

Screening for asymptomatic bacteriuria

Discussion of chemoprevention of breast cancer

Screening for breast cancer with mammography

Structured breastfeeding education and behavioral
counseling programs to promote breastfeeding

Screening for cervical cancer with Pap smear

Screening for chlamydia

Screening for colorectal cancer

Prevention of dental caries

Screening for depression

Screening for type 2 diabetes

continued ➤

Adults without hypertension or dyslipidemia: I

Children and adolescents: I

Preschool children, using risk assessment: I

No subgroups

Low risk women: C
Low risk pregnant women and age 26+: C
Men: I

Women over 65 who have had previous
negative screens: D
Women who have had total hysterectomy
for benign disease: D
Screening with new technologies: I
Screening with human papillomas virus test: I

Brief interventions or peer counseling to
promote breastfeeding: I

Screening with clinical breast exam or
breast self exam: I

Women not at increased risk of
breast cancer: D

Non-pregnant women and men: D

No subgroups

Adolescents: I

Never-smoking men ages 65 to 75: C
Women: D

COMMENTS

B – Recommended
C – No recommendation for or against (balance of harms and benefits too close to justify recomm.)
I – No recommendation for or against (insufficient evidence)

Ever-smoking men ages 65 to 75 years: B

Screening for abdominal aortic aneurysm

A – Strongly recommended
D – Recommended against

POPULATION

SERVICE

Recommended — Grade A (strongly recommended) and B (recommended)

Appendix 1: Recommendations of Current U.S. Task Force for Preventive Services (as of July 24, 2005)
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Newborns: A
Sexually active women, including those
who are pregnant if they are at high risk : B
Pregnant women: A
All adolescents and adults at increased risk: A
All pregnant women: A
Adults ages 18+: A
Men 35+, women 45+: A
Men 20 to 35, women 20 to 45 with
other risk factors: B
Screening including measurement
of total cholesterol and high density
lipoprotein cholesterol: B
Adults: B

Women ages 65+ and women 60 to 64
with risk factors: B
Increased risk and pregnant women: A
Adults: A
Pregnant women: A
Children younger than 5 years old: B

Screening for gonorrhea

Screening for hepatitis B

Screening for HIV

Screening for hypertension

Screening for lipid disorders

Screening for obesity with intensive
counseling and behavioral interventions

Screening for osteoporosis

Screening for syphilis

Screen for tobacco use and provide
tobacco cessation interventions

Visual impairment to detect amblyopia,
strabismus, visual field defect

No other subgroups

continued ➤

Screening for tobacco use or interventions
to prevent or treat tobacco use among
adolescents and children: I

Not increased risk: D

Women younger than age 60 and
women 60 to 64 without risk factors: C

Screening with low to moderate
intensity counseling: I
Counseling for overweight, not obese: I

Men 20 to 35, women 20 to 45 without
other risk factors: C
Screening including measurement
of triglycerides: I

Children and adolescents: I

All adolescents and adults
not at increased risk: C

General non-pregnant population: D

Men and women at low risk: D
Men at high risk: I
Pregnant women not at high risk: I

Routine behavioral counseling to promote
a healthy diet: I

COMMENTS

B – Recommended
C – No recommendation for or against (balance of harms and benefits too close to justify recomm.)
I – No recommendation for or against (insufficient evidence)

Adults with hyperlipidemia or other
risk factors for cardiovascular disease: B

Intensive behavioral dietary counseling

A – Strongly recommended
D – Recommended against

POPULATION

SERVICE

Recommended — Grade A and B (continued)

Appendix 1: Recommendations of Current USPSTF (July 24, 2005)
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Never-smoking men ages 65 to 75

Low risk women;
Low risk pregnant women and age 26+

All adolescents and adults not at
increased risk
Men ages 20 to 35 and women
ages 20 to 45 with no risk factors
Women younger than age 60 and
women 60 to 64 without risk factors

Screening for abdominal aortic aneurysm

Screening for chlamydia

Screening for HIV

Screening for lipid disorders

Screening for osteoporosis

Average risk
Men and non-pregnant women
Adults
Adults
Women not at increased risk of
breast cancer

Screening for bacterial vaginosis

Screening for asymptomatic bacteriuria

Beta carotene supplements

Screening for bladder cancer

Chemoprevention of breast cancer

continued ➤

Women at increased risk of breast cancer and
decreased risk of adverse events: B

No subgroups

Supplemental vitamins A, C, and E or folic
acid or antioxidant combinations: I

Pregnant women: A

High risk: I

Ever-smoking men ages 65 to 75: B
Never-smoking men ages 65 to 75: C

COMMENTS

Women ages 65+ and women 60 to 64
with risk factors: B

Men 35+ and women 45+: A

All adolescents and adults at increased
risk and all pregnant women: A

Increased risk women: A
Pregnant women at increased risk
and age 25 and younger: B
Men: I

Men who have ever smoked, ages 65 to 75: B
Women: D N either for or against — G

COMMENTS

B – Recommended
C – No recommendation for or against (balance of harms and benefits too close to justify recomm.)
I – No recommendation for or against (insufficient evidence)

Women

Screening for abdominal aortic aneurysm

A – Strongly recommended
D – Recommended against

POPULATION

SERVICE

Recommended against — Grade D

POPULATION

SERVICE

Although at least fair evidence exists that the service improves health outcomes, the Task Force concluded that the balance of
benefits and harms is too close to justify a general recommendation

No recommendation either for or against — Grade C
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Women over 65 who have had
previous negative screens
Women who have had total hysterectomy
for benign disease
Adults not at increased risk, using
electrocardiography, exercise treadmill test,
or electron-beam computerized tomography
Asymptomatic women
Asymptomatic adolescents and adults
Men and women at low risk

General population
Not at increased risk
Postmenopausal women:
Estrogen plus progestin, or estrogen alone
Adolescents
Women
Adults
Not increased risk
Men

Cervical cancer screening with Pap smear

Screening for coronary heart disease

Screening for genital herpes

Screening for gonorrhea

Screening for hepatitis B infection

Screening for hepatitis C

Postmenopausal hormone therapy
for primary prevention of chronic problems

Screening for idiopathic scoliosis

Screening for ovarian cancer

Screening for pancreatic cancer

Screening for syphilis

Screening for testicular cancer

No subgroups
continued ➤

Increased risk and pregnant women: A

No subgroups

No subgroups

No subgroups

No other subgroups

Increased risk: I

Pregnant women: A

Sexually active women, including those who are
pregnant if they are at high risk : B
Newborns: A
Men at high risk and pregnant women
at low risk: I

No other subgroups

Adults at increased risk: I

Women under 65 who are sexually
active and have a cervix: A
Screening with new technologies: I
Screening with human papillomavirus test: I

No other subgroups

COMMENTS

B – Recommended
C – No recommendation for or against (balance of harms and benefits too close to justify recomm.)
I – No recommendation for or against (insufficient evidence)

Postmenopausal women
Postmenopausal women who have
had a hysterectomy

Chemoprevention for hormone replacement therapy

A – Strongly recommended
D – Recommended against

POPULATION

SERVICE

Recommended against — Grade D (continued)
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Increased risk women
Women after child birth

Women ages 40+
Screening with new technologies
Screening with human papillomavirus test

Men

Adults at increased risk of coronary heart
diease events, using electrocardiography,
exercise treadmill test, or electron-beam
computerized tomography
Older adults
Preschool children, using risk assessment

Children and adolescents
Adults

Screening for bacterial vaginosis

Brief interventions or peer counseling
to promote breastfeeding

Breast cancer screening with clinical breast exam
or breast self exam

Screening for cervical cancer with Pap smear

Screening for chlamydia

Screening for coronary heart disease

Screening for dementia

Prevention of dental caries

Screening for depression

Routine behavioral counseling to promote
a healthy diet

continued ➤

Intensive behavioral dietary counseling for
adults with hyperlipidemia or other risk
factors for cardiovascular disease: B

Screening adults within a system of care: B

Preschool children, using oral fluoride supple
mentation in specific areas whose water is
deficient in fluoride: B

No subgroups

Adults not at increased risk: D

Increased risk women: A
Pregnant women at increased risk and age 25
and younger: B
Low risk women: C
Low risk pregnant women and age 26+: C

Women younger than age 65 who are
sexually active and have a cervix: A
Women older than age 65 who are not at high
risk or have had a total hysterectomy: D

Screening with mammography: B

Structured breastfeeding education and
behavioral counseling programs to promote
breastfeeding: B

Average risk: D

Adults: B

COMMENTS

B – Recommended
C – No recommendation for or against (balance of harms and benefits too close to justify recomm.)
I – No recommendation for or against (insufficient evidence)

Adolescents

Screening for alcohol misuse

A – Strongly recommended
D – Recommended against

POPULATION

SERVICE

No recommendation either for or against due to insufficient evidence — Grade I (continued)
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All pregnant women without previous diabetes
Adults without hypertension or dyslipidemia
Asymptomatic adults
Men at high risk
Pregnant women not at high risk

Increased risk
or sputum cytology
Children and adolescents
Adults
Smokers with low dose computerized
tomography or chest x-ray
Newborns
Adults
Adults
Adults
Adults
Men
All

Screening for gestational diabetes

Screening for type 2 diabetes

Screening for glaucoma

Screening for gonorrhea

Screening for hepatitis C infection

Screening for hypertension

Interventions to prevent low back pain

Screening for lung cancer

Newborn hearing screening

Screening for obesity with low to moderate
intensity counseling

Screening for oral cancer

Screening for overweight with any intensity counseling

Behavioral counseling to promote physical activity

Screening for prostate cancer with prostate-specific
antigen test and/or digital rectal examination

Counseling to prevent skin cancer

No subgroups

No subgroups

No subgroups

See above

No subgroups

continued ➤

Screening for obesity with intensive counseling
and behavioral interventions: B

No subgroups

No subgroups

No subgroups

Adults ages 18+: A

Not increased risk: D

Sexually active women, including those who
are pregnant if they are at increased risk: B
Men and women at low risk: D
Newborns: A

No other subgroups

Adults with hypertension or dyslipidemia: B

No subgroups

No subgroups

COMMENTS

B – Recommended
C – No recommendation for or against (balance of harms and benefits too close to justify recomm.)
I – No recommendation for or against (insufficient evidence)

Parents or guardians, women, older adults

Screening for family and intimate partner violence

A – Strongly recommended
D – Recommended against

POPULATION

SERVICE

No recommendation either for or against due to insufficient evidence — Grade I (continued)
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Adults
Adults
Adolescents and children
Adults

Screening for suicide risk

Screening for thyroid disease

Screen for tobacco use and provide tobacco
cessation interventions

Supplemental vitamins A, C, and E or folic acid
or antioxidant combinations

Beta carotene supplements: D

Adults and pregnant women: A

No subgroups

No subgroups

No subgroups

COMMENTS

Source: Agency for Healthcare Research and Quality, www.preventive services.ahrq.gov.

B – Recommended
C – No recommendation for or against (balance of harms and benefits too close to justify recomm.)
I – No recommendation for or against (insufficient evidence)

All

Screening for skin cancer with total body exam

A – Strongly recommended
D – Recommended against

POPULATION

SERVICE

No recommendation either for or against due to insufficient evidence — Grade I (continued)
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